FFO (TTM)

FFO/share (TTM)

FFO (Quarter)

FFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/FFO

Size (ft²)

Occupancy

Alexander’s, Inc. is a real estate investment trust (REIT) engaged in leasing, managing, developing and redeveloping properties. Alexander’s activities are conducted through its manager, Vornado Realty Trust. Alexander’s has seven properties in the greater New York City metropolitan area consisting of: 731 Lexington Avenue office and retail (including Bloomberg, L.P.'s world headquarters), the Rego Center complex in Rego Park, Queens, including the Rego Park I, II, and III retail properties and The Alexander apartment tower, and retail properties located in Paramus, NJ & Flushing, NY.

Alexander's Inc

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2023 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q3

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q4

Years since IPO: 15/15,
FFO Growth: 3/15,
FFO/share Growth: 3/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q2

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q3

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q4

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q1

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q3

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q4

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's FFO

FFO Growth

Assessment of recent increases in FFO per share, indicating profitability

FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Beverly Hills Private Wealth LLC lifted its position in shares of Alexander's, Inc. (NYSE: ALX) by 13.0% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 20,286 shares of the real estate investment trust's stock after buying an additional 2,332 shares during

Beverly Hills Private Wealth LLC Increases Position in Alexander’s, Inc. $ALX

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit.

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release.

ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

Innovative Industrial Properties (NYSE: IIPR - Get Free Report) and Alexander's (NYSE: ALX - Get Free Report) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership. Institutional and Insider Ownership 70.6% of Innovative

Alexander’s (NYSE:ALX) versus Innovative Industrial Properties (NYSE:IIPR) Critical Comparison

Stock News WBD reopens rival talks under Netflix waiver: Warner Bros. Discovery (WBD) received a seven-day waiver from Netflix (NFLX) to resume talks with Param

First Look: WBD waiver; Ackman's Meta bet; Ford-China JV

Alexander's, Inc. (NYSE: ALX - Get Free Report)'s share price traded down 16.4% during trading on Monday following a dissappointing earnings announcement. The stock traded as low as $212.38 and last traded at $213.1950. 40,119 shares were traded during mid-day trading, a decline of 55% from the average session volume of 89,063 shares. The stock had

Alexander’s (NYSE:ALX) Stock Price Down 16.4% After Earnings Miss

PARAMUS, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-K for the year ended December 31, 2025 today and reported:

Alexander's Announces Fourth Quarter Financial Results

PARAMUS, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on February 27, 2026 to stockholders of record on February 17, 2026.

Alexander's Declares Quarterly $4.50 Dividend on Common Shares

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the pricing of an underwritten offering of common stock and pre-funded warrants. ALX Oncology is selling 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,120 shares of common stock in the offering. The shares of common stock are being sold at an offering price of $1.57 per share, the closing price on January 29, 2026, and the pre-funded warrants are being sold at an offering price of $1.569 per pre-funded warrant, which represents the per share offering price for each share of common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to ALX Oncology from this offering are expected to be approximately $150 million, before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering are being offered by ALX Oncology. The offering is expected to close on or about February 2, 2026, subject to the satisfaction of customary closing conditions.

ALX Oncology Announces Pricing of Underwritten Offering

- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer –

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

PARAMUS, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its annual report on Form 10-K for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission and issue its fourth quarter and full year earnings release on Monday, February 9, 2026, before the New York Stock Exchange opens.

Alexander's Announces Fourth Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced its participation in the 44th Annual J.P.

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 –

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

PARAMUS, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it has restructured the $300 million mortgage loan on the retail condominium of 731 Lexington Avenue in Manhattan. Under the terms of the restructuring, the existing loan was split into a $132.5 million senior “A-Note” accruing current interest at 7.00% per annum and a $167.5 million junior “C-Note” accruing interest at 4.55% per annum, with a new maturity date of December 23, 2035.

Alexander's Completes Restructuring of Retail Loan at 731 Lexington Avenue

Alexander's, Inc. (NYSE: ALX - Get Free Report) saw unusually-high trading volume on Friday. Approximately 44,573 shares were traded during trading, an increase of 1% from the previous session's volume of 44,283 shares.The stock last traded at $217.3350 and had previously closed at $218.16. Analysts Set New Price Targets A number of brokerages have recently

Alexander’s (NYSE:ALX) Sees Strong Trading Volume  – Here’s What Happened

Alexander's, Inc. (NYSE: ALX - Get Free Report) shares saw an uptick in trading volume on Friday. 54,369 shares traded hands during trading, an increase of 25% from the previous session's volume of 43,607 shares.The stock last traded at $217.48 and had previously closed at $218.56. Analysts Set New Price Targets ALX has been the

SOUTH SAN FRANCISCO, CALIF., FEB. 19, 2026 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC. ("ALX ONCOLOGY; NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THAT ALX ONCOLOGY LEADERSHIP WILL PARTICIPATE IN THE WELLS FARGO EXECUTIVE BIOTECH SUMMIT, TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE, AND UBS BIOTECH SUMMIT.

ALX ONCOLOGY TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN Q1 2026

SOUTH SAN FRANCISCO, CALIF., FEB. 19, 2026 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC. ("ALX ONCOLOGY"; NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED PLANS TO REPORT ITS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND A BUSINESS UPDATE ON FRIDAY, FEBRUARY 27TH, 2026 BEFORE MARKET OPEN. THE COMPANY WILL HOST A TELECONFERENCE IN CONJUNCTION WITH ITS FINANCIAL RESULTS PRESS RELEASE.

ALX ONCOLOGY TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON FEBRUARY 27, 2026

PARAMUS, N.J., FEB. 09, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NEW YORK STOCK EXCHANGE: ALX) FILED ITS FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2025 TODAY AND REPORTED:

ALEXANDER'S ANNOUNCES FOURTH QUARTER FINANCIAL RESULTS

PARAMUS, N.J., FEB. 04, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS DECLARED A REGULAR QUARTERLY DIVIDEND OF $4.50 PER SHARE PAYABLE ON FEBRUARY 27, 2026 TO STOCKHOLDERS OF RECORD ON FEBRUARY 17, 2026.

ALEXANDER'S DECLARES QUARTERLY $4.50 DIVIDEND ON COMMON SHARES

SOUTH SAN FRANCISCO, CALIF., JAN. 30, 2026 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC. (ALX ONCOLOGY, NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS. ALX ONCOLOGY IS SELLING 76,979,112 SHARES OF COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 18,574,120 SHARES OF COMMON STOCK IN THE OFFERING. THE SHARES OF COMMON STOCK ARE BEING SOLD AT AN OFFERING PRICE OF $1.57 PER SHARE, THE CLOSING PRICE ON JANUARY 29, 2026, AND THE PRE-FUNDED WARRANTS ARE BEING SOLD AT AN OFFERING PRICE OF $1.569 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE OFFERING PRICE FOR EACH SHARE OF COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT. THE GROSS PROCEEDS TO ALX ONCOLOGY FROM THIS OFFERING ARE EXPECTED TO BE APPROXIMATELY $150 MILLION, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER ESTIMATED OFFERING EXPENSES, AND EXCLUDING THE EXERCISE OF ANY PRE-FUNDED WARRANTS. ALL SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS TO BE SOLD IN THE OFFERING ARE BEING OFFERED BY ALX ONCOLOGY. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT FEBRUARY 2, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

ALX ONCOLOGY ANNOUNCES PRICING OF UNDERWRITTEN OFFERING

- EXPLORATORY ANALYSIS FROM PHASE 1B/2 BREAST CANCER TRIAL REINFORCES CD47 AS A PREDICTIVE BIOMARKER FOR RESPONSE, AS PREVIOUSLY OBSERVED IN THE ASPEN-06 TRIAL IN HER2-POSITIVE GASTRIC CANCER 

NEW DATA DEMONSTRATE CD47 EXPRESSION LEVEL HELPS PREDICT RESPONSE TO ALX ONCOLOGY'S EVORPACEPT IN COMBINATION WITH ZIIHERA (ZANIDATAMAB-HRII) INADVANCED HER2-POSITIVE BREAST CANCER

PARAMUS, N.J., JAN. 21, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT IT WILL FILE ITS ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2025 WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION AND ISSUE ITS FOURTH QUARTER AND FULL YEAR EARNINGS RELEASE ON MONDAY, FEBRUARY 9, 2026, BEFORE THE NEW YORK STOCK EXCHANGE OPENS.

ALEXANDER'S ANNOUNCES FOURTH QUARTER EARNINGS RELEASE DATE AND VORNADO REALTY TRUST QUARTERLY CONFERENCE CALL

SOUTH SAN FRANCISCO, CALIF., JAN. 08, 2026 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC. ("ALX ONCOLOGY"; NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED ITS PARTICIPATION IN THE 44TH ANNUAL J.P.

ALX ONCOLOGY TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

PARAMUS, N.J., DEC. 29, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT IT HAS RESTRUCTURED THE $300 MILLION MORTGAGE LOAN ON THE RETAIL CONDOMINIUM OF 731 LEXINGTON AVENUE IN MANHATTAN. UNDER THE TERMS OF THE RESTRUCTURING, THE EXISTING LOAN WAS SPLIT INTO A $132.5 MILLION SENIOR A-NOTE ACCRUING CURRENT INTEREST AT 7.00% PER ANNUM AND A $167.5 MILLION JUNIOR C-NOTE ACCRUING INTEREST AT 4.55% PER ANNUM, WITH A NEW MATURITY DATE OF DECEMBER 23, 2035.

ALEXANDER'S COMPLETES RESTRUCTURING OF RETAIL LOAN AT 731 LEXINGTON AVENUE

PARAMUS, N.J., DEC. 09, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT IT HAS COMPLETED A $175 MILLION REFINANCING OF ITS 615,000 SQUARE FOOT REGO PARK II SHOPPING CENTER LOCATED IN QUEENS, NEW YORK. THE INTEREST-ONLY LOAN IS AT SOFR PLUS 2.00%, CURRENTLY 5.82%, AND MATURES IN DECEMBER 2030.

ALEXANDER'S COMPLETES $175 MILLION REFINANCING OF REGO PARK II

SOUTH SAN FRANCISCO, CALIF., NOV. 18, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., ("ALX ONCOLOGY" OR THE "COMPANY") (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THAT ALX ONCOLOGY LEADERSHIP WILL PARTICIPATE IN BOTH THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON AND PIPER SANDLER 37TH ANNUAL GLOBAL HEALTHCARE CONFERENCE IN NEW YORK.

ALX ONCOLOGY TO PRESENT AT UPCOMING INVESTOR CONFERENCES

SOUTH SAN FRANCISCO, CALIF., NOV. 07, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., (ALX ONCOLOGY OR THE COMPANY) (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A CORPORATE UPDATE.

Alexander's Inc

ALX

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

No items found.

Diversification by Country

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ALX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

No items found.

Diversification by Country

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ALX